Epidemiology for women aged 20 to 39 years cervical cancer remained the second leading cause of cancer deaths after breast cancer accounting for about 10 of cancer deaths Despite the declining death rates in ID: 530724
Download Presentation The PPT/PDF document "Carcinoma of the Cervix" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Carcinoma of the CervixSlide2
Epidemiology
for women aged 20 to 39 years, cervical cancer remained the second leading cause of cancer deaths after breast cancer, accounting for about 10% of cancer
deaths.
Despite the declining death rates in
developed countries cervical
cancer remains the leading cause of cancer deaths among women in many medically underserved countries, including many countries of Latin America, Africa, Asia, and eastern Europe.Slide3
کاهش مرگ در اثر کانسر سرویکس
routine
screening programs, including pelvic examinations and cervical
cytologic
evaluation
the
death rates from cervical cancer had begun to decrease before the implementation of
Papanicolaou
(Pap) screening, suggesting that other unknown factors may have played some role.Slide4
International incidencescultural
attitudes
screening programs
liberal
attitudes toward sexual behaviorSlide5
اتیولوژی
HPV
prostitutes
first coitus at a young
age
multiple
sexual
partners
bear
children at a young
age
Promiscuous sexual behavior in male partners
a
lower incidence of HPV infection in circumcised than uncircumcised males, with a correspondingly lower incidence of cervical cancer in their female partners.Slide6
prophylactic HPV vaccinea prophylactic HPV vaccine for women between the ages of
9 and 26 years
; this
quadrivalent
vaccine has been demonstrated to be highly effective in preventing
benign warts
and
neoplasia
caused by the most common HPV types (6, 11, 16, and 18).Slide7
علل عدم کاهش انسیدانس ادنوکارسینوما سرویکس
an increase in recognition of cases with glandular elements as adenocarcinomas
cytologic screening methods may be less effective in detecting adenocarcinomas at a preinvasive stageSlide8
ارتباط نقص ایمنی و کنسر سرویکس
T
he
relationship
between
immunosuppression
(particularly HIV-related
immunosuppression
) and the risk of HPV-related disease is complex and incompletely
understood.
Current data strongly suggest that HIV-related
immunosuppression
is correlated with an increased risk of cervical HPV infection
.
an
inverse correlation between CD4+ level and the risk of HPV infection, and patients with low CD4+ levels tend to have higher HPV DNA levels.Slide9
(
HIV) infection also appears to be associated with a higher prevalence of CIN and a faster rate of progression to high-grade CIN.
Iatrogenic
immunosuppression
is
also associated with an increased prevalence of
CIN.
risk of progression from CIN to invasive disease and on the virulence of invasive cervical cancer is less
certain
Antiretroviral therapy
does not appear to affect HPV levels, and
rarely
produces regression of CIN 2 or CIN 3 lesions, even with increases in CD4+ levels
.
Slide10
HIV-positiveOverlapping risk factors tend to confound studies of the association between HIV and HPV-related cancers. However, because of the increased risk of HPV infection in HIV-positive women, vigilant surveillance with
Pap smears
,
pelvic examinations
, and
colposcopy
(when indicated) should be part of the routine care of these women.Slide11
Natural History and Pattern of Spread
Most
arise
at the junction between the primarily columnar epithelium of the
endocervix
and the
squamous
epithelium of the
ectocervix
.
This
junction is a site of continuous
metaplastic
change, which is greatest
in
utero
,
at puberty
, and during
first pregnancy
, and declines after menopause. The greatest risk of
neoplastic
transformation coincides with periods of greatest
metaplastic
activity. Virally induced atypical
squamous
metaplasia
developing in this region can progress to higher-grade
squamous
intraepithelial lesions (SILs).Slide12
The mean age of women with CIN is about 15 years younger than that of women with invasive cancer, suggesting a slow progression of CIN to invasive
carcinoma. Slide13
Natural History and Pattern of Spread
CIN 3
disease progressed in only 14%, whereas it remained the same in 61% and disappeared in the others
spontaneous regression in 38% of high-grade HPV-associated SILs.
mean times to development of carcinoma in situ of 58, 38, and 12 months for patients with mild, moderate, or severe
dysplasia
, respectively, and predicted that 66% of all cases of dysplasia would progress to carcinoma in situ within 10 years.Slide14
Natural History and Pattern of Spread
exophytic
growths
endocervical
lesions
Tumor
may become fixed to the pelvic wall by direct extension or by coalescence of central tumor with regional
adenopathy
.
bladder
mucosal invasion.
Rectum invasion
Slide15
Three groups of lymphatics
The
upper
branches:
follow the uterine artery,
and
terminate in the uppermost
hypogastric
nodes
.
The middle branches drain to deeper
hypogastric
(
obturator
) nodes.
The
lowest branches follow a posterior course to the inferior and superior
gluteal
, common iliac,
presacral
, and
subaortic
nodes. Slide16
The incidence of pelvic and
para
-aortic node involvement is correlated with
tumor stage
and with other tumor characteristics, such as
size
,
histologic
subtype
,
depth of invasion
, and presence of
LVSI
stage
I
disease treated with
radical hysterectomy
, most investigators report
an incidence of positive pelvic nodes of 15% to 20% and an incidence of
para
-aortic nodes of 1% to 5%. Reported incidences are higher for patients with stage I disease treated with
radiation
: 10% to 25% of such patients are reported to have positive
para
-aortic nodes, reflecting the more advanced stage I tumors that are usually selected for treatment with radiation. Slide17
pattern of metastasCervical cancer usually follows a relatively orderly pattern of metastatic progression, initially to primary-echelon nodes in the pelvis and then to
para
-aortic nodes and distant sites.
Even
patients with
locoregionally
advanced disease rarely have detectable
hematogenous
metastases at initial diagnosis of their cervical cancer
.
The most frequent sites of distant recurrence are
lung
,
extrapelvic
nodes, liver, and boneSlide18
PathologySlide19
Cervical Intraepithelial Neoplasia
cervical
cytologic
findings
(important
characteristics
):
cellular immaturity
cellular disorganization
nuclear
abnormalities
increased
mitotic activity. Slide20
degree of neoplasia
extensiveness of the mitotic activity
immature cell proliferation
nuclear
atypia
If mitoses and immature cells are present only in the lower third of the epithelium, the lesion is usually designated CIN 1. Lesions involving only the lower and middle thirds are designated as CIN 2, and those involving the upper third are designated as CIN 3.Slide21
The term cervical intraepithelial
neoplasia
,
refers
only to a lesion that
may
progress
to invasive carcinoma. Although CIN 1 and CIN 2 are sometimes referred to as mild-to-moderate dysplasia,
CIN is now preferred over dysplasia
.
The Bethesda system of classification, designed to further standardize reporting of cervical
cytologic
findings, was developed Slide22
Squamous intraepithelial lesions
SILs include
Condyloma
dysplasia
,
CIN
The Bethesda system divides SILs
low
grade
high
grade(higher likelihood of progressing to invasive cancer)
)
CIN2,CIN3)Slide23
Bethesda system
atypical
squamous
cells of undetermined significance (ASCUS).
most common abnormal Pap smear result in United States
laboratories,
most
cases of ASCUS reflect a
benign
process, about 5% to 10% are associated with an underlying
HSIL
, and
one third or more of HSILs are heralded by a finding of ASCUS
on a Pap
smear.Slide24
three methods of management ASCUS or LSIL
immediate colposcopy
cytologic
follow-up
HPV DNA testing (ASCUS )
in patients with LSIL, the prevalence of high-risk HPV was too high to permit useful triage based on HPV DNA testing, but that in patients with ASCUS, HPV DNA testing had a sensitivity in the detection of HSIL similar to that of immediate
colposcopy
and reduced the number of referrals for
colposcopy
by 50%.Slide25
Adenocarcinoma In Situ
About 20% to 50% of women with cervical
adenocarcinoma
in situ also have
squamous
CIN
, and
adenocarcinoma
in situ is often an
incidental
finding in patients operated on for
squamous
carcinoma.
is frequently
multifocal
, cone biopsy margins are unreliable.
Although some investigators have described a possible precursor lesion termed
endocervical
glandular dysplasia, the reproducibility and clinical value of this designation are uncertainSlide26
Microinvasive Carcinoma
definition of
microinvasive
carcinoma is based on the maximum depth (no more than 5 mm) and linear extent (no more than 7 mm) of involvement.
This requires a
cervical cone biopsy
With the advent of
cytologic
screening, the proportion of invasive carcinomas that invade less than 5 mm has increased more than tenfold to about 20% in the United StatesSlide27
Microinvasive Carcinoma
The importance of LVSI remains somewhat controversial
the risk of metastatic regional disease appears to be exceedingly low for any tumor that invades less than 3 mm, even in the presence of LVSI.
many think that the risk of regional spread from tumors that have invaded 3 to 5 mm is sufficiently high to warrant treatment of the
parametria
and regional nodes.Slide28
Microinvasive adenocarcinomameasuring the depth of invasion can be difficult.
a subset of patients with very small
adenocarcinomas
have a low likelihood of lymph node metastases or recurrence. In the absence of a consensus definition of
microinvasion
for
adenocarcinoma
, decisions are usually guided by
specific descriptions of the depth and extent
of invasion and other features that have been correlated with increased risk, such as
high grade
and the
presence of LVSI.Slide29
Invasive Squamous Cell Carcinoma
A number of systems have been used to grade and classify squamous cell carcinomas, but none have consistently been demonstrated to predict prognosis
large cell keratinizing
large cell
nonkeratinizing
small cell carcinoma (poorer prognosis)
Papillary variants of
squamous
carcinoma
1.well differentiated (occasionally confused with immature
condylomata
)
2. very poorly differentiated (resembling high-grade transitional carcinoma)
Verrucous
carcinoma (
DDx
benign
condyloma
)
Sarcomatoid
squamous
carcinoma Slide30
Adenocarcinoma
pure or mixed with
squamous
cell carcinoma (
adenosquamous
carcinoma).
80% of cervical
adenocarcinomas
are of the
endocervical
type
Minimal-deviation
adenocarcinoma
(adenoma
malignum
) is a rare, extremely well-differentiated
adenocarcinoma
that is sometimes associated with
Peutz-Jeghers
syndrome.
Slide31
Adenocarcinoma
Other rare variants of
adenosquamous
carcinoma include
adenoid basal carcinoma (favorable prognosis)
adenoid cystic carcinoma(aggressive behavior )
endometrioid
, serous, or clear cells; mixtures of these cell typesSlide32
Anaplastic Small Cell/Neuroendocrine Carcinoma
Anaplastic
small cell carcinoma resembles oat cell carcinoma of the lung
About 30% to 50% of
anaplastic
small cell carcinomas display
neuroendocrine
features.
Widespread
hematogenous
metastasesSlide33
Other Rare Neoplasms
A variety of
neoplasms
may infiltrate the cervix from adjacent sites, and this makes differential diagnosis difficult. Although
endometrioid
histology suggests endometrial origin and
mucinous
tumors in young patients are most often of
endocervical
origin, both
histologic
types can arise in either site.
Metastatic tumors from the colon, breast, or other sites may involve the cervix secondarily.
Malignant mixed mullerian tumors,
adenosarcomas
, and
leiomyosarcomas
occasionally arise in the cervix but more often involve it secondarily.
Primary lymphomas and melanomas of the cervix are extremely rare.Slide34
Clinical Manifestations
Preinvasive disease during routine cervical cytologic screening.
Early invasive disease usually detected during screening examinations
abnormal vaginal bleeding, often following coitus or vaginal douching.
a clear or foul-smelling vaginal discharge
Pelvic pain
Flank pain (hydronephrosis complicated by pyelonephritis) The triad of sciatic pain, leg edema, and hydronephrosis is almost always associated with extensive pelvic wall involvement by tumor.
hematuria or incontinence from a vesicovaginal fistula
External compression of the rectum by a massive primary tumor may cause constipationSlide35
Diagnosis
an ideal target for cancer screening
cervical cytologic examination and pelvic examination has led to a decrease in the mortality rate
Only nations with well-developed screening programs have experienced substantial decreases in cervical cancer death ratesSlide36
Screening (The American Cancer Society)
3 years after
the onset of vaginal intercourse, but
no later than 21 years of age
annually with conventional cervical cytology smears
every 2 years using liquid-based Pap cytology
( until age 30 years)
Starting at age 30 years, women who have had three consecutive, technically satisfactory negative test results may be screened every 2 to 3 years. Slide37
موارد قطع اسکرینینگ
Women age 70 years and more who have had three consecutive
no abnormal test result within 10 years
who have had a total hysterectomy for benign gynecologic disease.
Women with a history of CIN 2 or CIN 3 prior to or as an indication for hysterectomy should be screened until they have had three consecutive normal test results and no abnormal test results for 10 years. Slide38
Women with a history of
cervical cancer
, women exposed in utero to diethylstilbestrol (
DES
), and women who are
immunocompromised
should
continue regular screening
as long as they are in reasonably good health.Slide39
The rate of false-negative findings on the Pap test is about
20% to 30% in women with high-grade CIN
10% to 15% in women with invasive cancer.
Slide40
Dx
Detection of
high endocervical lesions
may be improved when specimens are obtained with a cytobrush.
Because hemorrhage, necrosis, and intense inflammation may obscure the results, the Pap smear is a poor way to
diagnose
gross lesions
; these should always be biopsied.Slide41
the sensitivity of a screening program is usually increased by
repeated
annual testing. The sensitivity of individual tests may be improved by ensuring
adequate sampling of the squamocolumnar junction
and
the endocervical canal
; smears without endocervical or metaplastic cells are inadequate, and in such cases the test must be repeated. Because adenocarcinoma in situ originates near or above the transformation zone, it may be missed with conventional cervical smears. Slide42
liquid-based Pap methods greater sensitivity than conventional Pap smears.
the likelihood of drying artifact is reduced,
cellular sampling tends to be better
the cells are more evenly distributed on the slide.
Greater sensitivity comes at the cost of somewhat poorer specificity, which is balanced by the less frequent need for repetition of the study to achieve adequate screening. Slide43
HPV testing
although it is not yet recommended for routine screening, HPV testing of ASCUS smears followed by colposcopy in patients with HPV-positive lesions appears to provide a highly accurate and cost-effective means of
detecting HSIL
in equivocal smears.Slide44
Patients with abnormal findings on cytologic examination who do not have a gross cervical lesion must be evaluated with colposcopy and directed biopsies. Following application of a 3% acetic-acid solution, the cervix is examined under 10- to 15-fold magnification with a bright, filtered light that enhances the acetowhitening and vascular patterns characteristic of dysplasia or carcinoma. The skilled colposcopist can accurately distinguish between low- and high-grade dysplasia, but microinvasive disease cannot consistently be distinguished from intraepithelial lesions on colposcopy.Slide45
In a patient with an atypical Pap smear finding, if
no abnormalities are found on colposcopic
examination or if the
entire squamocolumnar junction cannot be visualized
, endocervical curettage should be performed. Some authorities advocate the routine addition of endocervical curettage to colposcopic examination to minimize the risk of missing occult cancer within the endocervical canal. However, it is probably reasonable to omit this step in previously untreated women if the entire squamocolumnar junction is visible with a complete ring of unaltered columnar epithelium in the lower canalSlide46
Cervical cone biopsy
is used to diagnose occult endocervical lesions and is an essential step in the diagnosis and management of microinvasive carcinoma of the cervix. Slide47
Cervical cone biopsy yields an accurate diagnosis and decreases the incidence of inappropriate therapy when (1) the squamocolumnar junction is poorly visualized on colposcopy and a high-grade lesion is suspected, (2) high-grade dysplastic epithelium extends into the endocervical canal, (3) the cytologic findings suggest high-grade dysplasia or carcinoma in situ, (4) a microinvasive carcinoma is found on directed biopsy, (5) the endocervical curettage specimens show high-grade CIN, or (6) the cytologic findings are suggestive of adenocarcinoma in situ.Slide48
Clinical Evaluation of Patients with Invasive Carcinoma
detailed history
physical examination,
complete blood cell count and renal function and liver function tests
chest radiography
intravenous pyelography (or computed tomography [CT])
Cystoscopy and either a proctoscopy or a barium enema study should be done in patients with bulky tumors.
CT S or MRI
PET
Slide49
CT S or MRI to evaluate regional nodes, but these studies have suboptimal accuracy because they fail to detect small metastases and because patients with bulky necrotic tumors often have enlarged reactive lymph nodes that may be free of metastasis.
PET appears to be a very sensitive noninvasive method of evaluating the regional nodes of patients with cervical cancer
74
and a useful method for following response to treatment,
80
although its high cost has prevented widespread routine use.
MRI can provide useful information about the distribution and depth of invasion of tumors in the cervix but tends to yield less accurate assessments of the parametrium.Slide50
International Federation of Gynecology and Obstetrics Staging of Carcinoma of the Cervix (1994)
0
Carcinoma in situ, intraepithelial carcinoma.
I
The carcinoma is strictly confined to the cervix (extension to the corpus should be disregarded)
IA
microscopically
Invasion is limited to measured
stromal
invasion with a maximum
depth of 5
mm and
no wider than 7 mm
.
Vascular space involvement, either venous or lymphatic, should not alter the staging).
IA1
Measured invasion of
stroma
no greater than 3 mm in depth and no wider than 7 mm.
IA2
Measured invasion of
stroma
greater than 3 mm and no greater than 5 mm in depth and no wider than 7 mm.
IB
Clinical lesions confined to the cervix or preclinical lesions greater than IA
IB1
Clinical lesions no greater than 4 cm in size
IB2
Clinical lesions greater than 4 cm in sizeSlide51
II
The carcinoma extends beyond the cervix, but has not extended onto the pelvic wall; the carcinoma involves the vagina, but not as far as the lower third
IIA
No obvious
parametrial
involvement
IIB
Obvious
parametrial
involvement.
III
carcinoma has extended onto the pelvic wall; on rectal examination there is no cancer-free space between the
tumour
and the pelvic wall; the
tumour
involves the lower third of the vagina; all cases with a
hydronephrosis
or nonfunctioning kidney should be included, unless they are known to be due to other cause.
IIIA
No extension onto the pelvic wall, but involvement of the lower third of the vagina
IIIB
Extension onto the pelvic wall or
hydronephrosis
or nonfunctioning kidney.Slide52
IV
The carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of the bladder or rectum
IVA
Spread of the growth to adjacent organs
IVB
Spread to distant organs.Slide53
Up todateTNM stage
FIGO stage
T1b =IB :Clinically visible lesion confined to the cervix or microscopic lesion greater than IA2
AJCC stage grouping
adenocarcinoma in situSlide54
Clinical Staging
FIGO stage is based on careful
clinical examination
and the results of
specific radiologic studies
and
procedures
.
The clinical stage should never be changed on the basis of subsequent findings.
When it is doubtful ,case should be assigned to the earlier stage. Slide55
Clinical Staging
According to FIGO,
growth fixed to the pelvic wall by a short and indurated, but not nodular, parametrium should be allotted to stage IIb.
A case should be classified as stage III only if the parametrium is nodular to the pelvic wall or if the growth itself extends to the pelvic wall.Slide56
FIGO rules for clinical staging,
Palpation
Inspection
Colposcopy
endocervical curettage
hysteroscopy
cystoscopy
Proctoscopy
intravenous urography
radiographic examination of the lungs and skeleton
.Slide57
Suspected bladder or rectal involvement should be confirmed by biopsy
Findings of bullous edema or malignant cells in cytologic washings from the urinary bladder are not sufficient to diagnose bladder involvementSlide58
FIGO specifically states that findings on examinations such as
lymphangiography
Laparoscopy
CT, and MRI :are of value for planning therapy but because these are not yet generally available and the interpretation of results is variable should not be the basis for changing the clinical stage
Examination under anesthesia is desirable but not required. Slide59
The rules and notes outlined in the FIGO staging system are integral parts of the clinical staging system and should be strictly observed to minimize inconsistencies in staging between institutions.Slide60
Although surgically treated patients are sometimes classified according to a TNM pathologic staging system, this practice has not been widely accepted because it cannot be applied to patients who are treated with primary radiotherapy.Slide61
Surgical Evaluation of Regional Spread
transperitoneal
extraperitoneal dissection
laparoscopic lymph node dissection ?
sentinel node ?Slide62
surgical staging(controversial)
identifies patients with microscopic para-aortic or common iliac node involvement
who can benefit from extended-field irradiation.
debulking of large pelvic nodes
before radiotherapy may improve outcome.
Because patients with radiographically positive pelvic nodes are at greatest risk for occult metastasis to para-aortic nodes, these patients may have the greatest chance of benefiting from surgical staging
Some authors have advocated pretreatment blind biopsy of the
scalene node
in patients with positive para-aortic nodes and in patients with a central recurrence who are being considered for pelvic exenteration. The reported incidence of supraclavicular metastasis varies widely (5% to 20% or more) for patients with positive para-aortic lymph nodes.Slide63
Prognostic Factors
FIGO stage
Clinical tumor diameter
presence of medial versus lateral parametrial involvement
presence of unilateral versus bilateral parametrial or pelvic wall involvement
Lymph node metastasis
LVSI
deep stromal invasion (10 mm or more or more than 70% invasion)
parametrial extension
inflammatory response
Uterine-body involvement ( distant metastases )
histologic features
histologic grade (adenocarcinomas)
HGB(locally advanced )Slide64
Operative findings often do not agree with clinical estimates of parametrial or pelvic wall involvement, and some authors have found that the predictive power of stage diminishes or is lost when comparisons are corrected for differences in clinical tumor diameter.Slide65
Other clinical and biologic features that have been investigated for their predictive power, with variable results, include :
Age
peritoneal cytology
platelet count
tumor vascularity
DNA ploidy or S phase
cyclooxygenase-2 expression
growth factor receptors.
HPV DNASlide66
Treatment
tumor size
stage
histologic features
evidence of lymph node metastasis
risk factors for complications of surgery or radiotherapy
patient preference. Slide67
Treatment
HSILs :loop electroexcision procedure (LEEP)
stage IA1: conservative surgery (excisional conization or extrafascial hysterectomy [type I])
stage IA2 and IB1 and some small stage IIA tumors: modified radical (type II) or radical (type III) hysterectomy or radiotherapy
stages IB2 through IVA: radiotherapy
Selected patients with centrally recurrent disease after RT may be treated with radical exenterative surgery
isolated pelvic recurrence after hysterectomy is treated with irradiation.
the routine addition of concurrent cisplatin-containing chemotherapy to radiotherapy for patients whose cancers have a high risk of locoregional recurrence.Slide68
Preinvasive Disease (Stage 0)
HSILs : (LEEP, LEEP conization, or excisional [cold knife] conization with a scalpel)
LEEP Conization: suspicion of occult invasion on cytologic or colposcopic examination
ablative therapy ( cryotherapy or CO
2
laser ablation )has declined
low-grade dysplasias are often followed without treatment
vaginal or type I abdominal hysterectomy for other gynecologic conditions that justify the procedureSlide69
LEEPa charged electrode is used to excise the entire transformation zone and distal canal. Although control rates are similar to those achieved with cryotherapy or laser ablation,
156
LEEP is more easily learned, is less expensive than laser ablation, and preserves the excised lesion and transformation zone for histologic evaluation.
However, low-grade lesions are overtreated with this method.
Slide70
LEEP conization or excisional conization with a scalpel
microinvasive suspected
invasive cancer suspected
adenocarcinoma in situ.
LEEP is an outpatient office procedure that preserves fertility. Although recurrence rates are low (1% to 5%) and progression to invasion rare (less than 1% in most series), patients require careful post-LEEP surveillance.Slide71
Microinvasive Carcinoma (Stage IA)
stage IA1 :conization or total (type I) or vaginal hysterectomy. pelvic lymphadenectomy is not usually recommended.
Patients who have FIGO stage IA1 disease without LVSI and who wish to maintain fertility may be adequately treated with a therapeutic cervical conization if the margins of the cone are negative. However, patients who have this conservative treatment must be followed closely with periodic cytologic evaluation, colposcopy, and endocervical curettage.Slide72
residua
The likelihood of residual invasive disease after cone biopsy is correlated with the status of the internal cone margin and the results of an endocervical curettage performed after cone biopsy.
The authors did not find any correlation between the depth of invasion or the number of invasive foci and residual invasion.Slide73
Therapeutic conization for microinvasive disease is usually performed with a scalpel while the patient is under general or spinal anesthesia. Because an accurate assessment of the maximum depth of invasion is critical, the entire specimen must be
sectioned and carefully handled to maintain its original orientation for microscopic assessment.
Complications occur in 2% to 12% of patients, are related to the depth of the cone, and include
hemorrhage
,
sepsis
,
infertility
,
stenosis
, and
cervical incompetence
.The width and depth of the cone should be tailored to produce the least amount of injury while providing clear surgical margins.Slide74
For (FIGO stage IA2), the risk of nodal metastases is approximately 5%.
Therefore, in such patients, a bilateral pelvic lymphadenectomy should be performed in conjunction with a modified radical (type II) hysterectomy.
Although surgical treatment is standard for in situ and microinvasive cancer, patients with severe medical problems or other contraindications to surgical treatment can be successfully treated with radiotherapy. Slide75
Stage IB and IIA Disease
Early stage IB cervical carcinomas can be treated effectively with combined external-beam irradiation and brachytherapy or with radical hysterectomy and bilateral pelvic lymphadenectomy. The goal of both treatments is to destroy malignant cells in the cervix, paracervical tissues, and regional lymph nodes.
Patients who are treated with radical hysterectomy whose tumors are found to have high-risk features may benefit from postoperative radiotherapy or chemoradiation.Slide76
stage IB
Overall survival rates between 80% and 90%,
)
with surgery
=
radiation
(
However, biases introduced by patient selection, variations in the definition of stage IA disease, and variable indications for postoperative radiotherapy, concurrent chemotherapy, or adjuvant hysterectomy confound comparisons about the efficacy of radiotherapy versus surgery. Because young women with small, clinically node-negative tumors tend to be favored candidates for surgery and because tumor diameter and nodal status are inconsistently described in published series, it is difficult to compare the results reported for patients treated with surgery or radiotherapy.Slide77
The authors reported a significantly higher rate of complications in the patients treated with initial surgery, and they attributed this finding to the frequent use of combined-modality treatment in this groupSlide78
stage IB1
Patient
preference
For patients with similar tumors, the overall rate of major complications is similar with surgery and radiotherapy, although urinary tract complications tend to be more common after surgical treatment and bowel complications are more common after radiotherapy. Surgical treatment tends to be preferred for young women with small tumors because it permits preservation of ovarian function and may cause less vaginal shortening. Radiotherapy is often selected for older, postmenopausal women to avoid the morbidity of a major surgical procedure.Slide79
stage IB2 (bulky)
radical hysterectomy
radical radiotherapy
However, patients who have tumors measuring more than 4 cm in diameter usually have deep stromal invasion and are at high risk for lymph node involvement and parametrial extension. Because patients with these risk factors have an increased rate of pelvic disease recurrence, surgical treatment is usually followed by postoperative irradiation, which means that the patient is exposed to the risks of both treatments. Consequently, many gynecologic and radiation oncologists believe that patients with stage IB2 carcinomas are better treated with radical radiotherapy.Slide80
concurrent administration of cisplatin-containing chemotherapy
bulky stage I cancers
lymph node metastasis
involved surgical margins
IB2<=Slide81
Patients who have stage IB1 cancers without evidence of regional involvement have excellent pelvic control rates (about 97% at 5 years) with radiotherapy alone and probably do not require chemotherapy when they are treated with primary radiotherapySlide82
Radical Hysterectomy
The standard surgical treatment for stage IB and IIA cervical carcinomas is radical (type III) hysterectomy and bilateral pelvic lymphadenectomy
Modified radical (type II) hysterectomy may be used for selected, small (less than 2-cm diameter) stage IB lesions. For premenopausal women (i.e., younger than 50 years), the ovaries usually are not removed. Ovarian metastases are rare in the absence of metastases to lymph nodes or other sites. If intraoperative findings suggest a need for postoperative pelvic irradiation, the ovaries may be transposed out of the pelvis.Slide83
postoperative complications
blood loss (mean, 0.8 liter)
ureterovaginal fistula (1% to 2%)
vesicovaginal fistula (less than 1%)
pulmonary embolus (1% to 2%)
small bowel obstruction (1% to 2%)
postoperative fever (25% to 50%) secondary
to:
deep vein thrombosis
pulmonary infection
pelvic cellulitis
urinary tract infection
wound infectionSlide84
Subacute complicationslymphocyst formation and lower-extremity edema
Lymphocysts may obstruct a ureter, but hydronephrosis usually improves with drainage of the lymphocyst.
The risk of complications may be increased in patients who undergo preoperative or postoperative irradiation.Slide85
Bladder complications
decreased bladder sensation
chronic bladder hypotonia or atony (3% to 5% )
Bladder dysfunction
stress incontinence(influenced by RT)
bladder contraction and instability(RT post s)
constipation and, rarely, chronic obstipation
small bowel obstruction(RT post s)Slide86
The use of
radical vaginal or abdominal trachelectomy
and
laparoscopic lymphadenectomy
has been advocated in carefully selected women with
small IB1
(2 cm or less) lesions who are eager to preserve fertility. The experience thus far suggests that the local control and survival rates with these procedures are similar to those in women who undergo a transabdominal radical or modified hysterectomy; however, fertility is clearly compromised: the percentage of women able to become pregnant and carry a baby to term is less than half the expected rate in women without cervical cancer; and there is a significant rate of prematuritySlide87
Radiotherapy After Radical Hysterectomy
irradiation decreases the risk of
pelvic recurrence
in patients whose tumors have high-risk features
it has been difficult to determine the
impact of adjuvant irradiation on survival.Slide88
CHRTAlthough pelvic irradiation reduces the risk of recurrence for patients with pelvic lymph node metastases or parametrial involvement, the risk of pelvic and distant recurrence remains high for these women
significantly improved rates of pelvic disease control and survival for patients who received chemotherapySlide89
Radical Radiotherapy
excellent survival and pelvic disease control rates in patients with stage IB cervical cancer.
Survival rates for patients with FIGO stage IIA disease treated with radiation alone range between 70% and 85% and are also strongly correlated with tumor size.
for patients with
bulky tumors
, results may be improved further with
concurrent administration of chemotherapySlide90
Radical radiotherapy
goal of radical radiotherapy =cervix, paracervical tissues, and regional LN
ERT+BT
Even small tumors that involve multiple quadrants of the cervix are usually treated with
total doses of 80 to 85 Gy to point A
. The dose may be reduced by 5% to 10% for very small superficial tumors. Although patients with small tumors may be treated with somewhat smaller fields than patients with more advanced locoregional disease, care must still be taken to adequately cover the
obturator
,
external iliac
,
low common iliac
, and
presacral nodes
. Slide91
Irradiation Followed by Hysterectomy
low pelvic recurrence rates after concurrent treatment with chemotherapy and radiation, suggest that there is little role for routine treatment with adjuvant hysterectomy. Slide92
adjuvant hysterectomy
uterine fibroids or other anatomic variations
involvement of the uterine fundus
In these cases, an extrafascial (type I) hysterectomy is usually performed, in which the uterus, cervix, adjacent tissues, and a small cuff of the upper vagina in a plane outside the pubocervical fascia are removed. This procedure involves minimal disturbance of the bladder and ureters. Slide93
Chemotherapy Followed by Radical Surgery?
A number of investigators have investigated the use of neoadjuvant chemotherapy followed by radical hysterectomy to treat patients with bulky stage IB or stage II cervical carcinomas.
Neoadjuvant chemotherapy has usually included cisplatin and bleomycin plus one or two other drugs. Slide94
Stage IIB, III, and IVA Disease
With appropriate chemoradiotherapy, even patients with massive locoregional disease have a significant chance for cure.
The success of treatment depends on a careful
balance
between external-beam radiotherapy and brachytherapy that optimizes the
dose
to tumor and normal tissues and the
overall duration
of treatment.
5Ys of 65% to 75%, 35% to 50%, and 15% to 20% are reported for patients treated with radiotherapy alone for stage IIB, IIIB, and IV tumorsSlide95
Stage IIB, III, and IVA Disease
External-beam irradiation
An initial course of external irradiation may also improve the efficacy of subsequent intracavitary treatment by
shrinking bulky tumor
and bringing it within the range of the high-dose portion of the brachytherapy dose distribution. For this reason, patients with locally advanced disease usually begin with a course of external-beam treatment. Subsequent brachytherapy exploits the inverse square law to deliver a high dose to the cervix and paracervical tissues while minimizing the dose to adjacent normal tissues.Slide96
Stage IIB, III, and IVA Disease
Although many clinicians delay intracavitary treatment until pelvic irradiation has caused some initial tumor regression,
breaks between external-beam and intracavitary therapy should be discouraged
, and every effort should be made to complete the
entire treatment in less than
7 to 8 weeks
.
several studies in patients with locally advanced cervical cancer have suggested that longer treatment courses are associated with decreased pelvic disease control and survival rates.Slide97
External-Beam Radiotherapy Technique
High-energy photons (15 to 18 MV) are usually preferred for pelvic treatment because they spare superficial tissues that are unlikely to be involved with tumor. At these energies, the pelvis can be treated either with four fields or with AP-PA alone .
When high-energy beams are not available, four fields are usually used because less-penetrating 4- to 6-MV photons often deliver an unacceptably high dose to superficial tissues when only two fields are used.Slide98
External-Beam Radiotherapy Technique
CT simulation (iliac lymph nodes.)
Information gained from radiologic studies such as MRI, CT, and PET improve estimates of disease extent and assist in localization of regional nodes and paracervical tissues that may contain microscopic disease.
The
caudad extent
of disease (radiopaque markers )
organ motion
to
use the simpler technique for patients with bulky tumors
.Slide99
Tumor response should be evaluated with periodic pelvic examinations to determine the best time to deliver brachytherapy.
a central block after 40GySlide100
central block
it can also result in overdoses to medial structures such as the ureters or underdosage of posterior uterosacral disease. For these reasons, other clinicians prefer to give an initial dose of 40 to 45 Gy to the whole pelvis, believing that the ability to deliver a homogeneous distribution to the entire region at risk for microscopic disease and the additional tumor shrinkage achieved before brachytherapySlide101
External-beam doses of more than 40 to 45 Gy to the central pelvis tend to compromise the dose deliverable to paracentral tissues and increase the risk of late complications.
96Slide102
Radiation therapy fields for cervical cancer
Conventional anteroposterior, AP (A), and lateral (B) radiation portals for cervical cancer defined by a superior field border at the L4-L5 disk space, a inferior border extending 3 to 4 cm below the lowest extent of disease or the bottom of the obturator foramen, and a lateral edge 1.5 to 2 cm lateral to the pelvic brim. Slide103
Pelvic radiation therapy field with vaginal marker
Radiograph (A) and computed tomography (CT) scan (B) demonstrating a radiopaque vaginal marker, placed to aid in localization of the vagina for treatment planning. Slide104
Parametrial boost for cervical cancer
Treatment fields for a parametrial boost for a stage IIB cervical cancer.Slide105
Extended field radiation therapy (EFRT) for cervical or endometrial cancer
Extended field anteroposterior (AP) radiation portal covering the para-aortic nodes. Slide106
IMRT
In particular, there has been considerable interest in the use of IMRT to treat the pelvis in patients with endometrial and cervical cancer. Unlike standard two-field and four-field techniques, IMRT makes it possible to deliver a lower daily dose to the intrapelvic contents than to surrounding pelvic lymph nodes .
reduced bone marrow toxicity and acute gastrointestinal side Slide107
IMRT
IMRT is less sparing of bowel.
IMRT allows delivery of doses exceeding 60 Gy with relative sparing of adjacent critical structures.
increase error
influence of internal organ motion and intratreatment tumor response on the doses to tumor and critical structures.Slide108
There is no evidence that IMRT can safely be used as an alternative to brachytherapy for routine treatment of intact cervical cancer.
IMRT cannot accurately reproduce the high-dose gradients produced with intracavitary therapy.
unpredictable variations mandate the use of large treatment marginsSlide109
Role of Para-Aortic Irradiation
para-aortic node involvement :25% to 50% enjoy long-term survival after extended-field irradiation .
even 10% to 15% of patients with gross lymphadenopathy appear to be curable with aggressive management.
Survival is also strongly correlated with the bulk of central disease.
patients who had small primary disease that could be controlled with radiotherapy demonstrates that extensive regional spread can occur without distant metastases and that patients with para-aortic node metastases can often be cured if their primary disease can be sterilized.Slide110
occult disease can be cured if the para-aortic nodes are included in the radiation fields
concurrent chemotherapy
PET and minimally invasive surgery add to the expense of treatment and are still infrequently performed in patients with locally advanced cervical cancer, these methods may provide better means of identifying patients with regional metastases
who can benefit from extended regional irradiationSlide111
Radiation Therapy Techniques
External irradiation is used to treat the whole pelvis and the parametria including the common iliac and para-aortic lymph nodes
central disease (cervix, vagina, and medial parametria) is primarily irradiated with intracavitary sources. Slide112
External-beam pelvic irradiation is delivered before intracavitary insertions in patients with:
Bulky cervical lesions or tumors beyond stage IIA to improve the geometry of the intracavitary application;
Exophytic, easily bleeding tumors;
Tumors with necrosis or infection
Parametrial involvement.Slide113
high-risk featuresparametrial involvement, deep stromal invasion, or positive nodes, positive or close operative margins, Slide114
Volume Treated
the primary tumor and the pelvic lymph nodes
superior border at the L4-5 (external iliac and hypogastric lymph node)
inferior border at the
inferior edge of the ischium
This margin must be extended to the L3-4 interspace if common iliac nodal coverage is indicated.
1.5-cm -2.5 cm margin on the pelvic rim;
Posterior extension of the
cardinal ligaments
in their attachment to the pelvic side wall was consistently posterior to the rectum and extended to the sacral hollow. The
uterosacral ligaments
also extended posteriorly to the sacrum. These anatomic landmarks must be kept in mind in the correct design of lateral pelvic portals.Slide115
lateral field
the anterior border of the lateral fields over the anterior edge of the pubic symphysis
the posterior at the S2-3 interspace
Three-dimensional treatment planning for pelvic irradiation of cervical carcinoma may reduce the treated volume, but further research must be done to determine whether the complication rate can be decreased as well.Slide116
For stage IB disease, : 15 by 15 cm at the surface (
For patients with stage IIA, IIB, III, and IVA carcinoma, (18 by 15 cm at surface) are required to cover all of the common iliac nodes in addition to the cephalad half of the vagina
If there is no vaginal extension, the lower margin of the portal is at the inferior border of the
obturator foramen.
When there is vaginal involvement, the entire length of this organ should be treated down to the introitusSlide117
In patients with tumor involving the
distal half
of the vagina, the portals should be modified to cover the
inguinal lymph nodes
because of the increased probability of metastases
the posterior margin usually is designed to cover at least 50% of the rectum in stage IB tumors, and it should extend to
the sacral hollow
in patients with more advanced tumorsSlide118
Midline Shielding in Ap–PA Portals
Depending on the institution and brachytherapy dose administered, midline shielding with rectangular or specially designed blocks are used for a portion of the external beam dose delivered with the
Ap–PA
ports Slide119
Parametrial Boost
When parametrial tumor persists after 50 to 60 Gy is delivered to the parametria, an additional 10 Gy in five or six fractions may be delivered with reduced AP-PA portals (8 by 12 cm for unilateral and 12 by 12 cm portals for bilateral parametrial coverage). The central shield should be in place to protect the bladder and rectum.Slide120
Para-Aortic Lymph Node Irradiation
If para-aortic node metastases are present or suspected, patients are treated with 45 to 50 Gy to the para-aortic area plus a
5 to 10 Gy
boost to enlarged lymph nodes through reduced lateral or rotational portals. With conventional techniques, the para-aortic lymph nodes are irradiated either with an extended field that includes both the para-aortic nodes and the pelvis or through a separate portalSlide121
separate portal
In this case, a “gap calculation( excessive dose to the small intestines)
The upper margin = T12-L1
lower margin at L5-S1
The width of the para-aortic portals (in general, 8 to 10 cm) can be determined by CT scans, MRI, lymphangiography, FDG-PET scans, or IV pyelography outlining the ureters.
The spinal cord dose (T12 to L2-3) should be kept below 45 Gy by interposing a 2-cm wide 5–half-value layer (HVL) shield on the posterior portal (usually after 40-Gy tumor dose) or using lateral ports and the kidneys below 1,800 cGySlide122
Beam Energies
10 MV or higher
They decrease the dose of radiation delivered to the peripheral normal tissues (particularly bladder and rectum) and provide a more homogeneous dose distribution in the central pelvis.
With lower-energy photons (Cobalt-60 or 4- to 6-MV x-rays), higher maximum doses must be given, and more complicated field arrangements should be used to achieve the same midplane tumor dose (3 or 4field pelvic box or rotational techniques) while minimizing the dose to the bladder and rectum and to avoid subcutaneous fibrosisSlide123
a metallic prosthesis when using lateral fields or a box pelvic irradiation technique may result in a dose decrease of approximately 2% for 25-MV x-rays and average increases of 2% for 10-MV x-rays and 5% for
60
Co.Slide124
Hyperfractionated Radiation Therapy for Locally
Advanced Cervix Cancer
1.2 Gy to the whole pelvis twice daily at 4- to 6-hour intervals, 5 days per weeka total pelvic dose of 57.5 Gy.A boost dose with brachytherapy Slide125
Concomitant Boost
On Monday, Wednesday, and Friday of the last 3 weeks, an additional 1.6-Gy boost was given 6 hours after the whole pelvis treatment (14.4 Gy) through lateral fields encompassing the parametria and primary tumor, for a total tumor dose of 59.4 Gy.
A single LDR brachytherapy procedure was performed within 1 week after the external-beam radiation therapy to raise the point A dose to 85 to 90 Gy in 42 days. Mean total treatment time was 46 days. Slide126
Three-Dimensional or IMRT
Bladder-filling control and accurate definition of margins for the PTV with image-guided position verification have been advocated to achieve a better application of IMRT.
patients with stage IIB or IVA cervical cancer with
medical illness
or
severe tumor-related anatomic
distortion that limited delivery of brachytherapy. IMRT was used to provide a simultaneous boost dose to the primary tumor at the time of external-beam treatment to a larger pelvic field given in conventional fractions. The toxicity of IMRT was acceptable, and early tumor responses were encouraging.Slide127
IMRT
Although not as critical in older patients, it is important to keep in mind that while IMRT has dosimetric advantages over conventional RT, IMRT exposes a greater amount of normal tissues to lower irradiation levels, which has the potential to increase the incidence of radiation-induced
second cancers
.Slide128
Brachytherapy
(
137
Cs) is the most popular LDR source
(
192
Ir) for HDR
Brachytherapy can be delivered with intracavitary techniques using a variety of applicators consisting of an intrauterine tandem and vaginal colpostats or, when necessary, vaginal cylinders, the majority of which are afterloading. Radiographs are always obtained using dummy sources, and the active sources can be inserted after the films have been reviewed and the position of the applicators judged to be satisfactory .
The vaginal packing is contrast material to identify it on the radiographs.Slide129
Remote afterloader for(HDR) brachytherapy
A remote afterloader stores a single (HDR) radioactive source, typically Ir-192, and through a computer controlled mechanism advances it within the catheter or applicator that has been placed in the patient.Slide130
(HDR) cervix brachytherapy applicators
Intrauterine tandem with (A) vaginal ovoids, with (B) vaginal cylinders, or with a (C) vaginal ring.Slide131
Cervical interstitial brachytherapy
Syed-type interstitial implant used for cervical brachytherapySlide132
Brachytherapy reference points
Tandem and ovoid cervical brachytherapy illustration of point A. Slide133
High dose rate (HDR) cervical brachytherapy planning
Orthogonal radiographs, (A) and (B), depicting placement of intrauterine tandem and vaginal ovoids. The images show the instruments in place in the uterus and vagina. In addition, there is barium contrast in the rectum, contrast in the Foley catheter balloon and radiopaque vaginal packing. Slide134
Vaginal cuff brachytherapy applicators
Vaginal ovoids (A) and vaginal cylinders (B) for vaginal cuff brachytherapy for endometrial cancerSlide135
For LDR treatments, the median pelvic EBRT dose was 45 to 50 Gy and the LDR brachytherapy dose was 42 and 45 Gy for early and advanced cancers, respectively.
For HDR treatments, the median EBRT dose was 48 to 50 Gy and the median HDR dose was 29 and 30 Gy for early and advanced cancers, respectively.
The median HDR dose per fraction was
6 Gy
with a median of
five fractions
.
Interstitial brachytherapy was used as a component of treatmentSlide136
computer-generated dose distributions provide the
best means
of determining the doses to point A, point B, bladder, and rectum
In general, an intrauterine tandem with three or four sources [15 or 20-10-10-(10) mCi mgRaEq with LDR] is inserted in the uterus and two colpostats (2 cm in diameter, loaded with 20 mCi mgRaEq LDR sources) are placed in the vaginal vault and packed with iodoform gauze to deliver 0.6 to 0.8 Gy per hour to point A.Slide137
miniovoids (usually loaded with 10 mCi mgRaEq LDR sources).
Special attention should be paid to obtain as symmetric and homogeneous dose distribution as is technically allowed by the geometry of the cervix/vagina and the configuration of the tumor. When even miniovoids cannot be inserted, it is better to use a protruding source in the vaginal vault, which is inserted in the afterloading tandem (usually 20 to 30 mCi mgRaEq) with an overlying plastic sleeve (3 cm in diameter).Slide138
With
HDR
intracavitary applicators the use of a
rectal retractor
has been shown to substantially reduce the rectal dose
Interstitial implants with radium (
226
Ra),
137
Cs needles, or
192
Ir afterloading plastic catheters to limited tumor volumes are helpful in specific clinical situations (e.g., localized residual tumor, parametrial extension. Slide139
Further, the American Endocurietherapy Society recommended that mgh and mgRaEq be replaced by the integrated reference air-kerma.
As Fletcher emphasized, conditions for an adequate intracavitary insertion include the following
The geometry of the insertion must prevent underdosing around the cervix;
Sufficient dose must be delivered to the paracervical areas; and
Vaginal mucosal (and, we add, bladder and rectal) tolerance doses must be respected.Slide140
Biology of High–Dose-Rate Brachytherapy for Cervical Carcinoma
Late damage rises sharply as the number of HDR fractions is decreased.
Displacing the bladder and rectum away from the HDR sources for the short duration of therapy may offset the radiobiologic disadvantage of using a few brachytherapy fractions Slide141
Clinical Experience
There is increasing use of HDR sources in brachytherapy of carcinoma of the cervix; basic principles of brachytherapy are similar to those of LDR Slide142
At Washington University, patients are treated with HDR brachytherapy with a tandem or a vaginal cylinder, which is placed in the patient before each treatment with sedation and without anesthesia. An
indwelling bladder catheter
is used during the procedure, and
gentle packing of the vagina
with iodoform gauze helps to maintain the applicators in place. Their position is
verified
with anteroposterior and lateral pelvic radiographs taken before the actual HDR treatment in each application.
The usual dose per fraction prescribed at 0.5-cm depth is 3 to 6 Gy, and three to six fractions are given once or twice weeklySlide143
Most HDR insertions are performed weekly and are interdigitated by giving four fractions of EBRT per week with one HDR treatment per week
The number of HDR fractions used to treat cervical cancer varies among centers from as few
as
two
to more than
10
. The optimal time–dose–fractionation scheme and the technique for remote-control
afterloading intracavitary brachytherapy for cervical cancer have
yet to be established
through systematic clinical trialsSlide144
n vivo bladder and rectal dosimetry is performed during the HDR procedure
Other centers obtain normal tissue doses from points located on dosimetry films and dose distribution curvesSlide145
Treatment planning for HDR brachytherapy can be accomplished by a variety of techniques, ranging from use of
an atlas of applications
and
source loadings
, to planning of only the initial insertion followed by replicating the insertion for subsequent treatments, to
customized optimization
of source loading for each HDR insertion Slide146
The optimal time–dose–fractionation scheme for HDR brachytherapy for cervical cancer has yet to be establishedSlide147
The American Brachytherapy Society published recommendations for HDR brachytherapy for carcinoma of the cervix
Each institution should follow
a consistent treatment policy
point A to at least a total LDR equivalent of 80 to 85 Gy for early stage disease and 85 to 90 Gy for advanced-stage disease.
The pelvic sidewall :50 to 55 Gy for early lesions and 55 to 65 Gy for advanced ones.
As with LDR BT, every attempt should be made to keep the bladder and rectal doses below 80 Gy and 75 Gy LDR-equivalent doses, respectively. Slide148
5.Interstitial brachytherapy should be considered when the tumor cannot be optimally encompassed by intracavitary brachytherapy.
6. It was emphasized that the responsibility for the medical decisions ultimately rests with the treating radiation oncologist.Slide149
Doses of Radiation
Stage IA (microinvasive) tumors are treated with intracavitary therapy only (LDR 60 Gy in one insertion or 75 to 80 Gy in two insertions to point A, or HDR 35 to 42 Gy in five to six insertions of 7 Gy to point A, one or two fractions per week).
The optimal dose for invasive carcinoma of the cervix is delivered with a combination of EBRT whole pelvis, intracavitary, and, at times, interstitial therapy. Slide150
Some institutions such as ours use lower doses of whole pelvis external irradiation (10 Gy for stage IB and 20 Gy for stages IIA, IIB, and III) in addition to parametrial doses to complete 50 Gy in stage IB and IIA or 60 Gy to the involved parametrial tissues for more advanced stages.
At Washington University, step-wedges designed in accordance with the isodose curves of the intracavitary applications are used to block the midline Slide151
We tend to reduce the total doses by 10% in women older than 70 years.Slide152
Illustration of IMRT treatment plan to irradiate pelvic lymph nodes, while sparing organs at risk.Slide153
Brachytherapy
Fletcher described three conditions that should be met for successful cervical brachytherapy:
(1) the geometry of the radioactive sources must prevent underdosed regions on and around the cervix
(2) an adequate dose must be delivered to the paracervical areas
(3) mucosal tolerance must be respected.Slide154
high-dose rate (HDR)
pulsed dose-rate,
interstitial brachytherapy
low-dose rate (LDR)
Brachytherapy is usually delivered using afterloading applicators that are placed in the uterine cavity and vagina. A number of different intracavitary systems have been usedSlide155
The intrauterine tandem and vaginal applicators are carefully positioned, usually with the patient under anesthesia, to provide an optimal relationship between the system and adjacent tumor and normal tissues.
Vaginal packing is used to hold the tandem and colpostats in place and to maximize the distance between the sources and the bladder and rectum
. Radiographs should be obtained at the time of insertion to verify accurate placement, and the system should be repositioned if positioning can be improved.Slide156
Encapsulated radioactive sources are inserted in the applicators after the patient has returned to her hospital bed, reducing exposure to personnel during applicator placement. Today, many practices are using remote afterloading units that employ an iridium source that is used to deliver a single dose at HDR or multiple pulsed doses delivered at hourly or greater intervals (pulsed dose-rate therapy)Slide157
a single stepping source that travels through the applicator tubes, pausing for varying times in a series of dwell positions to deliver the desired dose to adjacent tissues.
The activity of sources used for HDR or pulsed dose-rate brachytherapy is approximately 10 Ci and 0.5 to 1 Ci, respectively.
Because a computer controls insertion of the source, exposure to personnel is negligible with HDR or pulsed dose-rate methods. Slide158
Brachytherapy DoseIdeal placement of the uterine tandem and vaginal ovoids produces a pear-shaped distribution, delivering a high dose to the cervix and paracervical tissues and a reduced dose to the rectum and bladder Slide159
Paracentral doses are most frequently expressed at a single point, usually designated
Point A
. This reference point has been calculated in a number of different ways.
The most accepted definition of Point A is a point 2 cm lateral to the cervical collar and 2 cm above the top of the colpostats, measured at their intersection with the tandem midpoint on the lateral radiograph
an alternative definition places Point A 2 cm lateral and vertical to the external cervical os. These definitions can produce quite different dose estimates. Point A usually lies approximately at the crossing of the ureter and the uterine artery, but it bears no consistent relationship to the tumor or target volume. Slide160
Point A uses
It was meant to be used in the context of a detailed set of
rules governing the placement and loading of the intracavitary system
and was intended to be used primarily as a means of
reporting treatment intensity
, not as the sole parameter for treatment prescription. Today this context is often lost.Slide161
Whatever system of dose specification is used, emphasis should always be placed on optimizing the relationship between the
intracavitary applicators
and
the cervical tumor
and
other pelvic tissues
. Source strengths and positions should be carefully chosen to provide optimal tumor coverage without exceeding normal tissue tolerance. However, optimized source placement can rarely correct for a poorly positioned applicator.Slide162
Concurrent Chemoradiation
addition of concurrent cisplatin-containing chemotherapy to standard radiotherapy reduces the risk of disease recurrence by as much as 50%, thereby improving the rates of pelvic disease control and survival
stage IIB-IVA disease Slide163
RT , CHRTthe Radiation Therapy Oncology Group also conducted a trial in which radiotherapy alone (including prophylactic para-aortic irradiation) was compared with pelvic irradiation plus concurrent cisplatin and 5-FU
highly significant differences were detected in the rates of
local control
,
distant metastasis
,
overall survival
, and
disease-free survival
favoring the treatment arm that included chemotherapy. Although acute toxic effects of treatment were greater with chemotherapy, the dose and duration of radiation were similar in the two armsSlide164
Taken together, the randomized trials provide strong evidence that the addition of concurrent cisplatin-containing chemotherapy to pelvic radiotherapy benefits selected patients with locally advanced cervical cancer.
However, all of the studies explicitly excluded patients with evidence of
para-aortic lymph node metastases
,
poor performance status
, or
impaired renal function
.
Slide165
radiosensitizing effects
cisplatin
epirubicin
mitomycin
5-FU
are being studied :
Paclitaxel
carboplatin,
and several biologic response modifiersSlide166
Extended RT +CHTExtended-field irradiation (including the aortic nodes) has proven effective in the treatment of patients with known or suspected aortic-node metastasis but the role of extended-field irradiation needs to be clarified in the context of these new results. Combinations of extended-field irradiation and chemotherapy appear to be feasible, but their acute toxicity is considerable, and late toxicity may be greater than with extended-field radiotherapy alone.Slide167
Neoadjuvant Chemotherapy with Radiotherapy
CHT RT
بی نتیجه
CHT
CRT
تست نشده
CHT
تنها
OUTCOME
پاسخ ، بدون تغییر
despite the high rate of response of locally advanced cervical cancers to
neoadjuvant chemotherapy
, randomized studies have demonstrated
little or no improvement in outcome
with the addition of neoadjuvant chemotherapy to
radical radiotherapy. Slide168
chemotherapy.Stage IVB Disease
Single-Agent Chemotherapy
Combination Chemotherapy
Patients who present with disseminated disease are almost always incurable. The care of these patients must emphasize palliation of symptoms with use of appropriate pain medications and localized radiotherapy. Tumors may respond to chemotherapy, but responses are usually brief.Slide169
Cisplatin
Ifosfamide
, carboplatin,
irinotecan
, paclitaxel response rates of 10% to 20%
Single-Agent ChemotherapySlide170
Combination Chemotherapy
combination chemotherapy can improve both
progression-free survival
(cisplatin plus paclitaxel vs. single-agent cisplatin, cisplatin plus topotecan vs. single-agent cisplatin) and overall survival (cisplatin plus
topotecan)
when it is administered as treatment for recurrent or metastatic carcinoma of the cervix.
cisplatin plus topotecan :a median overall survival of 9.4 months, compared with 6.5 months (P = .17) for single-agent cisplatin.
Slide171
Palliative Radiotherapy
Localized radiotherapy can provide effective relief of pain caused by metastases in bone, brain, lymph nodes, or other sites. A rapid course of pelvic radiotherapy can also provide excellent relief of pain and bleeding for patients who present with incurable disseminated diseaseSlide172
Special Treatment Problems
Treatment of Locally Recurrent Carcinoma of the Cervix
Patients should be evaluated for possible recurrent disease if a new mass develops; if, in irradiated patients, the cervix remains bulky or nodular or cervical cytologic findings are abnormal
3 months
or more after irradiation; or if symptoms of leg edema, pain, or bleeding develop after initial treatment.
The diagnosis must be confirmed with
a tissue biopsy
, and the extent of disease should be evaluated with appropriate radiographic studies, cystoscopy, proctoscopy, and serum chemistry studies before treatment is administered.Slide173
After Radical Surgery
The treatment of choice for patients who have an isolated pelvic recurrence after initial treatment with radical hysterectomy alone is aggressive radiotherapy.
T
X
isolated
vaginal recurrence
Implants
may need to be inserted under laparoscopic or laparotomy guidance
.Slide174
After Radical SurgeryTX Pelvic wall recurrences are often treated with external-beam irradiation alone, although
surgery
and
intraoperative therapy
may contribute to local control in selected patients. Reported survival rates usually range between 20% and 40% for patients treated with radical radiotherapy.
2Slide175
After Definitive Irradiation
an
isolated central recurrence
can
be cured with surgical treatment.
Less extensive operations, such as
radical hysterectomy
or
anterior exenteration
, are reserved for selected patients with small tumors confined to the cervix or lesions that do not encroach on the rectum, respectively.Slide176
After Definitive Irradiation
contraindication for
pelvic
exenteration
involvement of the pelvic sidewall
The
triad of unilateral
leg edema
,
sciatic pain
, and
ureteral obstruction
almost always indicates unresectable disease on the sidewall.
Although advanced age is usually considered
aSlide177
After Definitive Irradiation
preparation
for total pelvic
exenteration
counseling of the patient and family
inspection
of the
abdomen
30
% of operations are aborted intraoperatively
.
Frozen section
biopsiesSlide178
After Definitive Irradiation
complications
The surgical
mortality rate is less than 10%,
with most postoperative complications and deaths related to sepsis, pulmonary thromboembolism, and intestinal complications such as small bowel obstruction and fistula formation. The rate of gastrointestinal complications may be reduced by using unirradiated segments of bowel and by closing pelvic floor defects with omentum, rectosigmoid colon, or myocutaneous flaps.
Advances in low colorectal anastomosis and techniques for creating continent urinary reservoirs have improved the quality of life for selected patientsSlide179
quality of patients' lives after surgical salvage
At
all points of evaluation, the patients' quality of life was most affected by
worries about the progression of the tumor
.
Ostomies
vaginal reconstruction
urostomy or colostomy.
Vaginal dryness and vaginal dischargeSlide180
The 5-year survival rates for patients who undergo anterior or total pelvic exenteration are 33% to 60% and 20% to 46%, respectively.
Unresectable
disease
: Several
groups are exploring the role of intraoperative irradiation in the treatment of selected patients with recurrent disease that involves the pelvic wall.
However, most patients who have unresectable pelvic recurrences after radiotherapy are treated with chemotherapy alone (previously discussed); response rates and prognosis are generally poor.Slide181
Unresectable diseaseIntraoperative
irradiation
(
involves the
pelvic
wall)
chemotherapy
alone (previously discussed); response rates and prognosis are generally poor.Slide182
Treatment After Simple Hysterectomy that Reveals Unsuspected Invasive Cancer
planned
hysterectomy should be carefully screened
invasion
of less than 3 mm without LVSI usually require
no treatment
after simple hysterectomy.
more
extensive disease
: with
postoperative radiotherapy or, in selected cases, with radical parametrectomy and lymphadenectomy.Slide183
posthysterectomy treatment
(1) microinvasive cancer,
(2) tumor confined to the cervix with negative surgical margins,
(3) positive surgical margins but no gross residual tumor,
(4) gross residual tumor by clinical examination documented by biopsy
(5) patients referred for treatment more than 6 months after hysterectomy (usually for recurrent disease).
5-year survival rates of 79% and 59% for patients in groups 2 and 3, respectively. (groups 4 and 5) was 41%Slide184
Carcinoma of the Cervical Stump
more extensive involvement who have
negative margins
are treated with 45 to 50 Gy of pelvic radiotherapy to treat the pelvic nodes and paracolpal tissues. Most clinicians follow this with vaginal intracavitary therapy, delivering an additional vaginal surface dose of 30 to 50 Gy.
ERT+BT
positive margins
: higher
dose of
ERTthrough
reduced fields designed to include the region at highest risk (e.g., parametria and posterior bladder wall).
RT+CHT
should
probably be considered for patients with group
3 or 4
disease(M+)Slide185
Carcinoma of the Cervical Stump
The natural history, staging, and workup of cervical stump carcinomas are the same as for carcinomas of the intact uterusSlide186
Carcinoma of the Cervical Stump
stage IA1: simple trachelectomy
selected patients with stage IA2 or small stage IB tumors : radical trachelectomy and pelvic lymph node dissection
most patients with irradiation alone using a combination of ERT
+
BT.
If possible, the cervix should be probed at the beginning of treatment to determine the length of the uterine canal. MRI may be an important aid to treatment planning in these patientsSlide187
endocervical
canal is 2 cm or longer, and after
ERT,
patients can be adequately treated with intracavitary therapy. The endocervical canal is usually loaded with 20 to 30 mgRaEq of cesium, depending on the length of the endocervical canal, and vaginal ovoids are loaded according to their diameter and position. Remote afterloading systems provide somewhat greater flexibility in source loading
.
If the endocervical canal cannot accommodate any sources,
a
boost
dose
may be delivered to the tumor with interstitial therapy or transvaginal irradiation. Vaginal ovoids alone rarely deliver an adequate dose to the cervix. Slide188
If brachytherapy is impossible, some patients can be cured using reduced fields of external-beam irradiation. However, brachytherapy should be used whenever
possible
.
When brachytherapy is used, most investigators have reported survival rates similar to those for patients with carcinomas of the intact cervix.Slide189
Carcinoma of the Cervix During Pregnancy
0.02% to 0.9%( invasive cervical cancer during pregnancy )
0.5% and 5% (pregnancy in patients with invasive cervical cancer)Slide190
Carcinoma of the Cervix During Pregnancy
Delayed in Diagnosis
a careful pelvic examination and Pap smear at their first antenatal visit
Any suspicious lesion should be biopsied
If the Pap smear is positive for malignant cells and the diagnosis of invasive cancer cannot be made with colposcopy and biopsy, a diagnostic conization may be necessary. Because conization subjects the mother and fetus to complications, it should be performed only in the second trimester and only in patients with inadequate colposcopy and strong cytologic evidence of invasive cancer. Conservative conization under colposcopic guidance may reduce the risk.Slide191
delay definitive treatment
Carcinoma
in situ or stage IA disease until the fetus has matured
whose disease invades less than 3 mm and no LVSI
A
vaginal hysterectomy
6 weeks after childbirth
Patients whose disease invades 3 to 5 mm and those with LVSI may also be followed to
term The
infant may be delivered by
a cesarean section
, which is followed immediately by modified radical hysterectomy and pelvic lymph node dissection.Slide192
Modern neonatal care affords a 75% survival rate for infants delivered at 28 weeks of gestational age and 90% for those delivered at 32 weeks. Fetal pulmonary maturity can be determined by amniocentesis, and prompt treatment can be instituted when pulmonary maturity is documented. It is probably wise to avoid delays in therapy of more than 4 weeks whenever possible, although this guideline is controversial.
IB1 : classic
cesarean section followed by radical hysterectomy with pelvic lymph node dissection. Slide193
stage II-IV
, bulky
stage IB
: radiotherapy.
If the fetus is viable, it is delivered by classic cesarean section and radiotherapy is begun postoperatively. If the pregnancy is in the first trimester, external-beam irradiation can be started with the expectation that spontaneous abortion will occur before the delivery of 40 Gy. In the second trimester, a delay of therapy may be entertained to improve the chances of fetal survival. If the patient wishes to delay therapy, it is important to ensure fetal pulmonary maturity before delivery is undertaken.Slide194
cervical cancer
during
pregnancy have slightly
better overall survival because an increased proportion have stage I disease.
in
the postpartum period tends to be associated with a more advanced clinical stage and a corresponding decrease in
survival
Although
studies differ in their conclusions about whether pregnancy has an independent influence on the prognosis of patients with cervical cancer, recent case-matched studies have demonstrated similar survival rates for pregnant and nonpregnant patientsSlide195
Recurrence at episiotomyPatients who are diagnosed with invasive cervical cancer shortly after a vaginal delivery and who had an episiotomy appear to be at risk for recurrence at the site of their episiotomy. At least 13 cases demonstrating this unusual pattern of failure have been reported.